Duodenal Ulcer Healing with Four Antacid Tablets Daily

Weberg, R.; Berstad, Arnold; Lange, O.; Schultz, Tim; Aubert, Erik

doi:10.3109/00365528509088868

Cited by 60 publications

(11 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent study comparing famotidine's potency (on an equimolar basis) with the other H2 receptor antagonists in patients with Zollinger-Ellison syndrome, famotidine was 32-fold more potent than cimetidine and 9-fold more potent than ranitidine [26], In the same study, duration of action of famotidine was 30% longer than that of both cimetidine and ranitidine given in equipotent doses, an observation that confirms pre vious data [ 13,27,28]. These characteristics of famotidine may have influenced the re sults obtained in this study.…”

Section: Discussionsupporting

confidence: 72%

A Multicenter, Randomized, Double-Blind Study Comparing Famotidine with Cimetidine in the Treatment of Active Duodenal Ulcer Disease

Rodrigo¹,

Viver

Conchillo

et al. 1989

Digestion

View full text Add to dashboard Cite

The efficacy and safety of famotidine (40 mg at night), a new potent H₂-receptor antagonist, has been studied in 119 patients by four investigators in four Spanish hospitals in a randomized double-blind comparative study with cimetidine (800 mg at night). Antacid tablets were allowed as additional treatment, if needed for pain relief. There were no significant differences between the groups in baseline characteristics, including duodenal ulcer size. Efficacy parameters included daytime and nocturnal symptom relief and duodenal ulcer healing, documented by endoscopy, and defined as complete reepithelization of the ulcer crater. Endoscopy was performed at baseline and after 4 and 6 weeks of treatment. One hundred and five patients fulfilled the evaluation criteria (51 patients in the famotidine group and 54 in the cimetidine group). After 4 weeks, in 91.6% of the patients receiving famotidine and 82.3% of the patients receiving cimetidine ulcers were healed. After 6 weeks, healing rates were 96% (famotidine) and 85.1% (cimetidine) (p = 0.056). Pain relief was rapid in both treatment groups, with a tendency to better response during the day in the famotidine group. The intake of antacids, as well as the clinical and laboratory safety profile were similar for both groups.

show abstract

Section: Discussionsupporting

confidence: 72%

A Multicenter, Randomized, Double-Blind Study Comparing Famotidine with Cimetidine in the Treatment of Active Duodenal Ulcer Disease

Rodrigo¹,

Viver

Conchillo

et al. 1989

Digestion

View full text Add to dashboard Cite

show abstract

“…High oral doses of ΑΙ-containing phosphate binders are prescribed for these patients (5,17), and Al hydroxide, the compound most widely used in the formulation for phosphate regulation, may increase Al uptake (18) causes increased plasma Al and has been associated with toxicity (19). Aluminium in antacid form has also been widely prescribed in adults to prevent or treat gastric lesions and reduce the incidence of stress ulceration (1,2). In all these treatments, Al absorption depends on the chemical species of Al salts ingested.…”

Section: Discussion mentioning

confidence: 99%

“…Aluminium (Al), a ubiquitous contaminant, is routinely used in antacid form to prevent or treat gastric lesions, gastro-oesophageal reflux or oesophagitis in patients with normal renal function (1,2). Studies have shown an increase in serum Al levels in healthy subjects or in patients with chronic renal failure after oral ingestion of various compounds usually containing Al hydroxide (3) or sucralfate (4), respectively, as phosphate binders.…”

Section: Introductionmentioning

confidence: 99%

Absence of Gastrointestinal Absorption or Urinary Excretion of Aluminium from an Allantoinate Complex Contained in Two Antacid Formulations in Patients with Normal Renal Function

Guillard

Huguet²,

Fauconneau³

et al. 1996

CCLM

View full text Add to dashboard Cite

We studied the plasma and urinary excretion levels of aluminum (Al) on day 0, 10 and 30 in 79 patients with gastrointestinal symptoms and normal renal function who were receiving a complex based on Al allantoinates [C 4 H 5 N 4 O 3 Al (OH) 2 ] and [C 4 H 5 N 4 O 3 Cl A1 2 (OH) 4 ]. We evaluated the extent of Al absorption after repeated administration of this complex in two antacid formulations, Ulfon Lyoc® in lyophilised tablet form (group 1; n = 40) and Ulfon® suspension (group 2; n = 39). The total Al load for each antacid and patient was 512 mg daily for a total of 15360 mg during the 30-day treatment. No significant rise in plasma Al concentration was noted with either formulation between day 0 and 10, day 0 and 30 or day 10 and 30, nor was there any significant increase in urinary excretion levels. Al absorption was not increased and no toxic effects were noted, indicating that such formulations are suitable for long-term therapy in patients with gastrointestinal symptoms.

show abstract

“…They bind pepsin and urease and may reduce the number of Helicobacter pylori on the stomach mucosa. Even in low doses antacids have remarkable effects on the healing of peptic ulcers [18,19,20,21,22]. These effects might be consequences of aluminium hydroxide’s ability to bind enzymes and bacteria.…”

Section: Discussionmentioning

confidence: 99%

Sucralfate Protects Blood Clots from Peptic Digestion by Gastric Juice in vitro

Berstad²

2006

Digestion

View full text Add to dashboard Cite

Objective: To test in vitro the ability of sucralfate to protect a blood clot from peptic digestion by gastric juice. Material and Methods: Blood clots adhering to the bottom of plastic tubes were exposed to native acidic gastric juice or gastric juice to which Al-Mg antacids, sucralfate or alkali had been added. The tubes were tilted regularly at room temperature and clot digestion monitored by measuring the diameters of the clots. After 15 h, the liquids, but not the adherent clots, were poured out and the tubes refilled with native acidic gastric juice. Further clot digestion was measured, as before. Results: Native gastric juice digested the clots completely during approximately 7 h, while in neutralized gastric juice or in gastric juice containing antacids or sucralfate no digestion was seen. In the second experiment, native gastric juice completely digested all remaining clots, except those previously exposed to sucralfate. A dose-response study indicated that gastric juice containing 3% or more of sucralfate had this long-lasting, clot-protective effect. Conclusions: In vitro, sucralfate adheres to and protects blood clots from digestion by gastric juice pepsin. This unique effect of sucralfate may be of clinical relevance in the treatment of bleeding peptic ulcers.

show abstract

Duodenal Ulcer Healing with Four Antacid Tablets Daily

Cited by 60 publications

References 9 publications

A Multicenter, Randomized, Double-Blind Study Comparing Famotidine with Cimetidine in the Treatment of Active Duodenal Ulcer Disease

A Multicenter, Randomized, Double-Blind Study Comparing Famotidine with Cimetidine in the Treatment of Active Duodenal Ulcer Disease

Absence of Gastrointestinal Absorption or Urinary Excretion of Aluminium from an Allantoinate Complex Contained in Two Antacid Formulations in Patients with Normal Renal Function

Sucralfate Protects Blood Clots from Peptic Digestion by Gastric Juice in vitro

Contact Info

Product

Resources

About